Echs1 Antibody

What is ECHS1 and why is it significant in research?

ECHS1 is a multifunctional mitochondrial matrix enzyme that catalyzes the second step of the β-oxidation pathway in fatty acid metabolism. Beyond its role in fatty acid metabolism, ECHS1 is involved in the oxidation of essential amino acids such as valine and has been implicated in sphingolipid metabolism regulation. Research significance stems from its connections to various cancers, including colorectal, liver, gastric, and renal cancers, as well as its role in mitochondrial encephalopathy when deficient . The ECHS1 gene is mapped to human chromosome 10q26.2–q26.3 and encodes eight exons. Due to its involvement in multiple cellular processes, ECHS1 antibodies have become essential tools for investigating metabolic pathways, cancer biology, and inherited mitochondrial disorders .

What are the primary applications for ECHS1 antibodies in basic research?

ECHS1 antibodies are primarily utilized in the following basic research applications:

• Immunohistochemistry (IHC) - For detecting ECHS1 expression in tissue samples. The standard protocol involves overnight incubation with primary antibodies at 4°C, followed by Mayer's hematoxylin for nuclear counterstaining .

• Western blot analysis - For quantifying ECHS1 protein levels in cell or tissue extracts and monitoring protein degradation kinetics when combined with cycloheximide (CHX) treatment .

• Co-immunoprecipitation (Co-IP) assays - For investigating protein-protein interactions, particularly useful for identifying ECHS1 binding partners such as LASP1 .

• Immunofluorescence studies - For examining subcellular localization, particularly mitochondrial localization patterns.

• Prognostic biomarker evaluation - For correlating ECHS1 expression levels with cancer progression and patient outcomes in clinical samples .

How should ECHS1 antibody specificity be validated for research use?

Validating ECHS1 antibody specificity requires multiple complementary approaches:

• Western blot validation - Confirm the antibody detects a single band of the expected molecular weight (~31 kDa) in positive control samples, with absent or significantly reduced signal following ECHS1 knockdown or knockout.

• Immunoprecipitation controls - Verify the antibody can successfully pull down ECHS1 protein that can be subsequently detected by a different ECHS1 antibody or by mass spectrometry.

• Immunohistochemistry validation - Compare staining patterns between tissues known to express high ECHS1 levels (such as liver or heart) versus tissues with ECHS1 deficiency.

• Overexpression validation - Demonstrate increased signal in cells overexpressing ECHS1 versus control cells.

• Cross-reactivity assessment - Test the antibody against closely related mitochondrial proteins to ensure specificity.

Published research with ECHS1 antibodies employed 1:500 dilutions for both western blot and IHC applications, which may serve as a starting point for optimization in new experimental systems .

How can ECHS1 antibodies be used to investigate protein-protein interactions?

ECHS1 antibodies are valuable tools for exploring protein-protein interactions through several advanced approaches:

• Co-immunoprecipitation (Co-IP) - This technique has successfully identified ECHS1's interaction with LASP1. In the published research, protein extracts from SW480 cells were used for Co-IP assays to verify ECHS1-LASP1 binding .

• Domain mapping experiments - Using ECHS1 antibodies in conjunction with domain truncation experiments can identify specific binding regions. Research revealed ECHS1 binds to the SH3 domain of LASP1 through Co-IP assays with various LASP1 constructs: Flag-LASP1 (1–261a), Flag-LASP1 (1–131 aa), Flag-LASP1 (60–198 aa), and Flag-LASP1 (131–261 aa) .

• Protein stability assays - ECHS1 antibodies can monitor protein degradation kinetics after cycloheximide (CHX) treatment with or without potential interacting partners. This approach demonstrated LASP1's ability to prevent ECHS1 degradation, prolonging its half-life .

• Degradation pathway investigation - Using ECHS1 antibodies in combination with pathway inhibitors (such as chloroquine for lysosomal degradation or MG132 for proteasomal degradation) can determine the mechanism of protein turnover. This revealed LASP1 inhibits ECHS1 degradation by preventing its proteasomal hydrolysis .

• Proximity ligation assays - For visualizing and quantifying protein-protein interactions in situ at specific subcellular locations.

How can ECHS1 antibodies contribute to cancer research and drug resistance studies?

ECHS1 antibodies play a critical role in understanding cancer progression and drug resistance through several methodological approaches:

What are the methodological considerations when studying ECHS1 in mitochondrial disease models?

Investigating ECHS1 in mitochondrial disease models requires careful methodological approaches:

• Genetic confirmation - Before using ECHS1 antibodies in disease models, confirm pathogenic mutations through exome sequencing. Studies identified compound heterozygous or homozygous mutations in ECHS1 in patients with mitochondrial encephalopathy .

• Tissue-specific expression analysis - Different tissues show varying ECHS1 expression patterns, requiring optimization of antibody dilutions and detection methods for each tissue type. Heart and liver tissues typically show high ECHS1 expression and can serve as positive controls .

• Functional correlations - Combine antibody-based protein detection with enzymatic activity assays to determine how protein levels correlate with enzyme function in different disease models.

• Mitochondrial isolation considerations - When studying ECHS1 in isolated mitochondria, careful fractionation procedures are essential to maintain protein integrity for subsequent antibody detection.

• Patient sample handling - When working with limited clinical samples from patients with ECHS1 deficiency, consider using highly sensitive detection methods like chemiluminescence for western blotting or signal amplification techniques for immunohistochemistry.

• Phenotype correlation - Correlate antibody-detected ECHS1 expression levels with clinical manifestations such as encephalopathy, deafness, epilepsy, optic nerve atrophy, and cardiomyopathy to establish genotype-phenotype relationships .

How can ECHS1 antibodies be employed in sphingolipid metabolism research?

ECHS1 antibodies provide valuable tools for investigating sphingolipid metabolism through several methodological approaches:

• Co-expression studies - Use ECHS1 antibodies alongside antibodies against sphingolipid-metabolizing enzymes (like UGCG) to examine their correlation in different cellular contexts. Research demonstrated ECHS1 promotes UGCG, which catalyzes the first step of ceramide glycosylation to convert ceramide to glucosylceramide .

• Pathway manipulation experiments - After manipulating ECHS1 expression (overexpression or knockdown), use ECHS1 antibodies to confirm successful manipulation before measuring changes in sphingolipid metabolites through techniques like LC-MS. Studies showed ECHS1 alters ceramide metabolism by increasing glycosphingolipid synthesis (HexCer) .

• Inhibitor studies - Combine ECHS1 antibody-based detection with sphingolipid pathway inhibitor treatments. Research demonstrated that eliglustat, a specific UGCG inhibitor, reversed the effects of ECHS1 overexpression on drug resistance, suggesting ECHS1's action through the sphingolipid pathway .

• Multi-omics integration - Correlate ECHS1 protein levels (detected via antibodies) with metabolomic data on ceramide and glycosylated ceramide levels to establish functional relationships.

• Subcellular localization studies - Use ECHS1 antibodies in fractionation studies to determine where in the cell ECHS1 interacts with sphingolipid metabolism components.

This approach has revealed that ECHS1 contributes to cancer drug resistance by promoting UGCG-mediated ceramide glycosylation, which can be reversed by eliglustat treatment .

What analytical techniques can be combined with ECHS1 antibody detection for comprehensive pathway analysis?

To achieve comprehensive pathway analysis, ECHS1 antibody detection can be integrated with multiple analytical techniques:

• Mass spectrometry-based metabolomics - Combine ECHS1 protein quantification via antibodies with LC-MS analysis of lipid metabolites. This approach revealed ECHS1's role in altering ceramide metabolism by increasing glycosphingolipid synthesis .

• RNA-seq or qPCR - Correlate ECHS1 protein levels with transcriptomic changes in metabolic pathway genes to identify regulatory relationships.

• Enzyme activity assays - Pair ECHS1 antibody detection with functional assays measuring β-oxidation activity or ceramide glycosylation to establish structure-function relationships.

• Phosphorylation state analysis - Use phospho-specific antibodies alongside ECHS1 antibodies to monitor activation of signaling pathways like PI3K/Akt/mTOR, which was shown to be regulated by ECHS1 .

• ROS measurement techniques - Combine ECHS1 antibody detection with reactive oxygen species assays, as research demonstrated ECHS1 promotes cancer progression partly by modulating ROS levels .

• Mitochondrial function assays - Integrate ECHS1 protein detection with measurements of mitochondrial membrane potential, as ECHS1 was shown to interfere with this parameter in cancer cells .

This multi-modal approach provides mechanistic insights into how ECHS1 functions within metabolic networks and regulatory pathways.

What are the common challenges when using ECHS1 antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with ECHS1 antibodies, which can be systematically addressed:

• Background signal in western blots

  • Optimization strategy: Increase blocking time (2-3 hours), use alternative blocking agents (5% BSA instead of milk), and optimize primary antibody dilutions (starting at 1:500 as used in published research) .

  • Validation approach: Include ECHS1 knockout or knockdown samples as negative controls.

• Weak signal in immunohistochemistry

  • Optimization strategy: Employ antigen retrieval methods (citrate buffer pH 6.0 or EDTA buffer pH 9.0), increase antibody concentration, or extend incubation time (overnight at 4°C as used in published protocols) .

  • Validation approach: Include tissues known to express high levels of ECHS1 (liver, heart) as positive controls.

• Non-specific bands in co-immunoprecipitation

  • Optimization strategy: Use more stringent washing buffers, pre-clear lysates, and optimize antibody-to-bead ratios.

  • Validation approach: Perform reverse co-IP experiments to confirm interactions from both perspectives.

• Variable results across tissue types

  • Optimization strategy: Adjust fixation protocols for each tissue type and calibrate antibody concentrations accordingly.

  • Validation approach: Use multiple detection methods (IHC, western blot) to confirm findings.

• Cross-reactivity with related proteins

  • Optimization strategy: Employ higher antibody dilutions and more stringent washing conditions.

  • Validation approach: Test antibody specificity using recombinant ECHS1 protein alongside related mitochondrial proteins.

How should immunohistochemistry protocols be optimized for ECHS1 detection in different tissue types?

Optimizing IHC protocols for ECHS1 detection requires tissue-specific adjustments:

• Fixation considerations

  • For fatty tissues (liver): Use shorter fixation times (12-24 hours) with 10% neutral buffered formalin to prevent excessive cross-linking that might mask ECHS1 epitopes.

  • For brain tissues: Consider using 4% paraformaldehyde instead of formalin for better preservation of mitochondrial antigens.

• Antigen retrieval optimization

  • Heat-mediated retrieval: Test both citrate buffer (pH 6.0) and EDTA buffer (pH 9.0) to determine optimal conditions for exposing ECHS1 epitopes.

  • Enzymatic retrieval: Consider proteinase K treatment for heavily fixed tissues that resist heat-mediated retrieval.

• Antibody protocol adjustments

  • Primary antibody incubation: Published research used ECHS1 antibody at 1:500 dilution with overnight incubation at 4°C .

  • Detection system selection: For tissues with low ECHS1 expression, use amplification systems like tyramine signal amplification.

• Counterstaining optimization

  • Mayer's hematoxylin was successfully used for nuclear counterstaining in published ECHS1 studies .

  • Adjust counterstaining time carefully to maintain visibility of ECHS1 signals while providing adequate nuclear definition.

• Validation controls

  • Positive tissue controls: Include liver or heart tissues known to express high ECHS1 levels.

  • Negative controls: Include both primary antibody omission controls and tissues from ECHS1-deficient samples when available.

How can ECHS1 antibodies contribute to research on therapeutic interventions for ECHS1-related disorders?

ECHS1 antibodies offer valuable tools for developing and evaluating potential therapeutic approaches:

• Drug screening validation

  • ECHS1 antibodies can verify target engagement in high-throughput screening for compounds that stabilize mutant ECHS1 proteins.

  • Western blot analysis using ECHS1 antibodies can quantify changes in protein stability after drug treatment.

• Gene therapy assessment

  • Following gene therapy approaches, ECHS1 antibodies can confirm successful protein expression from the delivered gene constructs.

  • Immunohistochemistry with ECHS1 antibodies can verify tissue-specific expression patterns after targeted delivery.

• Drug efficacy monitoring

  • As demonstrated with eliglustat, ECHS1 antibodies can monitor pathway normalization after drug treatment. Research showed eliglustat reversed ECHS1-induced drug resistance and tumor growth in vivo .

  • Immunohistochemical staining showed eliglustat treatment (60 mg/kg) reversed the expression of pathway proteins activated by ECHS1, including p-mTOR and BCL2 .

• Biomarker development

  • ECHS1 antibody-based assays can help identify patient subpopulations most likely to benefit from specific interventions.

  • Correlation studies between ECHS1 expression patterns and clinical outcomes can guide personalized treatment approaches.

• Combination therapy evaluation

  • ECHS1 antibodies can help assess whether interventions targeting sphingolipid metabolism synergize with other therapeutic approaches.

  • The finding that ECHS1 promotes cancer progression and drug resistance through the PI3K/Akt/mTOR pathway suggests potential combination strategies with pathway inhibitors .

What role might ECHS1 antibodies play in understanding the relationship between metabolism and neurological disorders?

ECHS1 antibodies provide crucial tools for investigating the intersection of metabolism and neurological function:

• Neurodegenerative disease models

  • ECHS1 antibodies can detect protein expression changes in brain tissues from models of Leigh syndrome and other mitochondrial encephalopathies .

  • Immunohistochemical analysis can map regional vulnerabilities by identifying areas with altered ECHS1 expression.

• Metabolic stress response

  • Using ECHS1 antibodies alongside markers of oxidative stress can reveal how metabolic dysfunction leads to neuronal damage.

  • Research showed ECHS1 promotes cancer progression by releasing reactive oxygen species (ROS) , a mechanism potentially relevant to neurodegeneration.

• Developmental studies

  • ECHS1 antibodies can track protein expression during brain development, potentially identifying critical periods when ECHS1 deficiency most severely impacts neurological development.

  • This approach could explain why patients with ECHS1 mutations present with developmental delays and encephalopathy .

• Mitochondrial dynamics

  • Co-localization studies using ECHS1 antibodies with markers of mitochondrial fusion, fission, and mitophagy can reveal how metabolic disruption affects mitochondrial quality control.

  • This is particularly relevant as ECHS1 deficiency has been linked to mitochondrial encephalopathy .

• Cell-type specific vulnerability

  • ECHS1 antibodies in conjunction with cell-type specific markers can identify which neural cell populations are most sensitive to ECHS1 dysfunction.

  • This could explain the specific pattern of symptoms observed in patients with ECHS1 mutations, including deafness, epilepsy, and optic nerve atrophy .